marketcaparena
Search

    IOVA

    IOVANCE BIOTHERAPEUTICS, INC.

    Company overview

    Market capitalization
    $4.98B
    Employees
    975
    Latest publication
    2026-09-29
    About IOVANCE BIOTHERAPEUTICS, INC.

    Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20222022-06-30 · USDQ1 20222022-03-31 · USDQ2 20212021-06-30 · USDQ4 20202020-12-31 · USD
    Total Revenue99,313,000USD71,430,000USD86,771,000USD67,455,000USD0USD0USD0USD0USD
    Cost Of Revenue43,595,000USD1,019,000USD-100,527,000USD1,408,000USD5,203,000USD4,978,000USD488,000USD—
    Gross Profit55,718,000USD70,411,000USD187,298,000USD66,047,000USD-5,203,000USD-4,978,000USD-488,000USD—
    Research Development58,851,000USD62,487,000USD68,854,000USD75,174,000USD73,406,000USD68,300,000USD62,119,000USD52,451,000USD
    General And Administrative Expenses39,272,000USD———————
    Total Operating Expenses107,623,000USD151,454,000USD260,758,000USD160,948,000USD99,734,000USD91,713,000USD81,426,000USD68,534,000USD
    Operating Income-51,905,000USD-81,043,000USD-73,460,000USD-94,901,000USD-99,734,000USD-91,713,000USD-81,426,000USD-68,534,000USD
    Total Other Income Expense Net3,217,000USD1,333,000USD1,740,000USD1,243,000USD385,000USD106,000USD75,000USD137,000USD
    Interest Income3,217,000USD1,333,000USD1,740,000USD1,243,000USD385,000USD106,000USD75,000USD—
    Depreciation And Amortization9,500,000USD8,539,000USD3,929,000USD9,007,000USD5,248,000USD4,978,000USD2,777,000USD321,000USD
    Income Before Tax-48,688,000USD-79,710,000USD-71,720,000USD-93,658,000USD-99,349,000USD-91,607,000USD-81,351,000USD-68,397,000USD
    Income Tax Expense-1,373,000USD-665,000USD184,000USD-2,405,000USD-385,000USD-106,000USD-122,000USD—
    Net Income-47,315,000USD-79,045,000USD-71,904,000USD-91,253,000USD-99,349,000USD-91,607,000USD-81,351,000USD-68,397,000USD
    Selling General Administrative—38,949,000USD36,400,000USD34,555,000USD26,328,000USD23,413,000USD19,307,000USD16,083,000USD
    Unclassified Operating Expenses—50,018,000USD155,504,000USD51,219,000USD————
    Net Interest Income—1,333,000USD1,740,000USD1,243,000USD385,000USD106,000USD75,000USD137,000USD
    Tax Provision—-665,000USD184,000USD-2,405,000USD————
    Net Income From Continuing Ops—-79,045,000USD-71,904,000USD-91,253,000USD-99,349,000USD-91,607,000USD-81,351,000USD-68,397,000USD
    Ebit—-79,710,000USD-71,720,000USD-93,658,000USD-99,349,000USD-91,607,000USD-81,351,000USD-68,534,000USD
    Ebitda—-71,171,000USD-67,791,000USD-84,651,000USD-94,101,000USD-86,629,000USD-78,574,000USD-68,213,000USD
    Reconciled Depreciation—10,415,000USD12,644,000USD11,677,000USD5,248,000USD4,978,000USD366,000USD321,000USD
    Interest Expense————385,000USD106,000USD75,000USD137,000USD
    Non Operating Income Net Other————385,000USD106,000USD75,000USD137,000USD
    Net Income Applicable To Common Shares————-99,349,000USD-91,607,000USD-81,351,000USD-68,397,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USDFY 20142014-12-31 · USD
    Total Revenue238,000USD0USD0USD0USD0USD0USD0USD0USD
    Cost Of Revenue21,135,000USD13,980,000USD8,712,000USD8,122,999USD952,000USD978,000USD999,000USD88,221USD
    Gross Profit-21,135,000USD-13,980,000USD-8,712,000USD-8,122,999USD-952,000USD-978,000USD-999,000USD-9,336,000USD
    Research Development294,781,000USD259,039,000USD201,727,000USD166,023,000USD71,615,000USD28,037,000USD15,470,000USD2,705,000USD
    Selling General Administrative104,097,000USD83,664,000USD60,210,000USD40,849,000USD21,262,000USD25,602,000USD12,390,000USD9,336,000USD
    Total Operating Expenses398,878,000USD342,703,000USD261,937,000USD206,872,000USD92,877,000USD53,639,000USD27,860,000USD2,705,000USD
    Operating Income-398,878,000USD-342,703,000USD-261,937,000USD-206,872,000USD-92,877,000USD-53,639,000USD-27,860,000USD-12,040,000USD
    Interest Income2,985,000USD451,000USD2,356,000USD9,316,000USD813,000USD745,000USD200,000USD—
    Interest Expense2,985,000USD451,000USD2,356,000USD0USD0USD0USD200,000USD5,660USD
    Net Interest Income2,985,000USD451,000USD2,356,000USD9,316,000USD813,000USD745,000USD——
    Income Before Tax-395,893,000USD-342,252,000USD-259,581,000USD-197,556,000USD-92,064,000USD-52,894,000USD-27,660,000USD-12,035,000USD
    Income Tax Expense-5,970,000USD-14,431,000USD-2,356,000USD-10,485,000USD-952,000USD-978,000USD-999,000USD0USD
    Tax Provision0USD0USD——————
    Net Income-389,923,000USD-327,821,000USD-259,581,000USD-187,071,000USD-92,064,000USD-52,894,000USD-27,660,000USD-12,035,000USD
    Net Income From Continuing Ops-395,893,000USD-342,252,000USD-259,581,000USD-197,556,000USD-92,064,000USD-52,894,000USD-27,660,000USD-12,034,709USD
    Ebit-398,878,000USD-342,703,000USD-261,937,000USD-206,872,000USD-92,877,000USD-53,639,000USD-27,860,000USD-12,034,221USD
    Ebitda-377,743,000USD-328,723,000USD-260,797,000USD-205,703,000USD-91,925,000USD-52,661,000USD-26,861,000USD-11,946,000USD
    Depreciation And Amortization21,135,000USD13,980,000USD1,140,000USD1,169,000USD952,000USD978,000USD999,000USD88,221USD
    Reconciled Depreciation21,135,000USD13,980,000USD1,140,000USD1,169,000USD952,000USD———
    Total Other Income Expense Net2,985,000USD451,000USD2,356,000USD9,316,000USD813,000USD745,000USD200,000USD5,660USD
    Net Income Applicable To Common Shares-395,893,000USD-342,252,000USD-259,581,000USD-197,556,000USD-92,064,000USD-102,348,000USD-27,660,000USD-12,034,709USD
    Non Operating Income Net Other—451,000USD2,356,000USD9,316,000USD813,000USD745,000USD200,000USD5,660USD
    Unclassified Operating Expenses———————-9,336,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets915,531,000USD925,665,000USD913,170,000USD904,948,000USD907,437,000USD966,740,000USD910,426,000USD991,115,000USD
    Cash And Equivalents110,768,000USD———————
    Cash And Short Term Investments297,674,000USD313,443,000USD296,980,000USD300,803,000USD301,183,000USD359,713,000USD323,781,000USD397,488,000USD
    Short Term Investments186,906,000USD116,935,000USD133,902,000USD142,669,000USD168,714,000USD188,045,000USD208,087,000USD233,302,000USD
    Total Current Assets464,257,000USD466,502,000USD442,689,000USD429,091,000USD422,500,000USD512,649,000USD457,018,000USD498,578,000USD
    Other Current Assets8,874,000USD12,925,000USD11,583,000USD9,817,000USD11,546,000USD16,453,000USD12,377,000USD6,744,000USD
    Other Non Current Assets6,431,000USD———————
    Total Liabilities179,486,000USD———————
    Total Current Liabilities106,848,000USD129,420,000USD138,358,000USD125,785,000USD129,155,000USD122,693,000USD122,341,000USD118,056,000USD
    Total Stockholder Equity736,045,000USD721,754,000USD698,583,000USD702,287,000USD698,488,000USD767,865,000USD710,405,000USD773,455,000USD
    Total Equity Including Noncontrolling Interest736,045,000USD———————
    Net Receivables102,119,000USD81,758,000USD82,448,000USD66,760,999USD59,938,000USD70,938,000USD69,340,000USD55,768,000USD
    Inventory55,590,000USD58,376,000USD51,678,000USD51,710,000USD49,833,000USD65,545,000USD51,520,000USD38,578,000USD
    Property Plant Equipment Net174,944,000USD175,776,000USD177,011,000USD175,413,000USD172,422,000USD162,487,000USD164,282,000USD179,263,000USD
    Accounts Payable26,211,000USD37,450,000USD22,159,000USD31,237,000USD32,004,000USD28,489,000USD27,509,000USD31,686,000USD
    Short Term Debt2,673,000USD3,899,000USD4,043,000USD7,281,000USD8,070,000USD9,499,000USD12,896,000USD11,551,000USD
    Common Stock19,000USD18,000USD17,000USD16,000USD14,000USD14,000USD13,000USD13,000USD
    Retained Earnings-2,901,890,000USD-2,854,575,000USD-2,775,530,000USD-2,703,626,000USD-2,612,373,000USD-2,500,715,000USD-2,384,552,000USD-2,305,993,000USD
    Accumulated Other Comprehensive Income13,078,000USD12,650,000USD16,440,000USD16,103,000USD20,859,000USD6,294,000USD-1,046,000USD16,242,000USD
    Intangible Assets—269,104,000USD279,324,000USD285,208,000USD296,253,000USD285,356,000USD282,398,000USD306,639,000USD
    Total Liab—203,911,000USD214,587,000USD202,661,000USD208,949,000USD198,875,000USD200,021,000USD217,660,000USD
    Other Current Liab—88,071,000USD112,156,000USD87,267,000USD89,081,000USD84,705,000USD81,936,000USD74,819,000USD
    Capital Stock—20,000USD19,000USD18,000USD16,000USD16,000USD16,000USD16,000USD
    Cash—196,508,000USD163,078,000USD158,134,000USD132,469,000USD171,668,000USD115,694,000USD164,186,000USD
    Net Debt—-148,732,000USD-114,634,000USD-105,642,000USD-79,303,000USD-117,949,000USD-57,433,000USD-85,246,000USD
    Short Long Term Debt—1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD——
    Short Long Term Debt Total—47,776,000USD48,444,000USD52,492,000USD53,166,000USD53,719,000USD58,261,000USD78,940,000USD
    Property Plant Equipment Gross—228,149,000USD225,781,000USD220,737,000USD214,527,000USD201,250,000USD200,302,000USD216,088,000USD
    Common Stock Shares Outstanding—418,511,000shares406,966,000shares364,037,000shares334,511,000shares322,868,000shares304,890,000shares303,269,000shares
    Non Current Assets Total—459,163,000USD470,481,000USD475,857,000USD484,937,000USD454,091,000USD453,408,000USD492,537,000USD
    Non Current Liabilities Total—74,491,000USD76,229,000USD76,876,000USD79,794,000USD76,182,000USD77,680,000USD99,604,000USD
    Non Currrent Assets Other—14,283,000USD14,146,000USD9,271,000USD16,262,000USD6,248,000USD6,728,000USD280,000USD
    Net Working Capital—337,082,000USD304,331,000USD303,306,000USD293,345,000USD389,956,000USD334,677,000USD380,522,000USD
    Unclassified Non Current Liabilities—74,491,000USD76,229,000USD76,876,000USD79,794,000USD76,182,000USD76,680,000USD98,604,000USD
    Unclassified Equity—3,563,641,000USD3,457,637,000USD3,389,776,000USD3,289,972,000USD3,262,256,000USD3,095,974,000USD3,063,177,000USD
    Unclassified Non Current Assets———5,965,000USD———6,355,000USD
    Long Term Debt——————1,000,000USD1,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets913,170,000USD910,426,000USD780,351,000USD663,982,000USD777,333,000USD768,458,000USD344,655,000USD480,821,000USD
    Intangible Assets279,324,000USD282,398,000USD229,258,000USD—————
    Other Current Assets11,583,000USD12,377,000USD17,458,000USD7,271,000USD3,546,000USD6,663,000USD9,412,000USD13,702,000USD
    Total Liab214,587,000USD200,021,000USD195,738,000USD164,344,000USD155,674,000USD111,960,000USD45,684,000USD14,628,000USD
    Total Stockholder Equity698,583,000USD710,405,000USD584,613,000USD499,638,000USD621,659,000USD656,498,000USD298,971,000USD466,193,000USD
    Other Current Liab112,156,000USD81,936,000USD69,406,000USD52,295,000USD56,766,000USD35,074,000USD16,265,000USD11,659,000USD
    Common Stock17,000USD13,000USD11,000USD8,000USD7,000USD6,000USD5,000USD5,000USD
    Capital Stock19,000USD16,000USD14,000USD11,000USD10,000USD10,000USD9,000USD11,000USD
    Retained Earnings-2,775,530,000USD-2,384,552,000USD-2,012,375,000USD-1,568,338,000USD-1,172,445,000USD-830,193,000USD-570,612,000USD-372,760,000USD
    Cash163,078,000USD115,694,000USD114,888,000USD231,731,000USD78,229,000USD67,329,000USD13,969,000USD82,152,000USD
    Cash And Short Term Investments296,980,000USD323,781,000USD279,867,000USD471,845,000USD504,410,000USD629,437,000USD307,081,000USD468,523,000USD
    Total Current Assets442,689,000USD457,018,000USD307,848,000USD479,116,000USD507,956,000USD636,100,000USD316,493,000USD475,374,000USD
    Total Current Liabilities138,358,000USD122,341,000USD110,306,000USD91,485,000USD89,200,000USD54,871,000USD39,084,000USD14,398,000USD
    Net Debt-114,634,000USD-57,433,000USD-39,026,000USD-146,285,000USD-6,698,000USD-15,670,000USD-2,469,000USD-82,152,000USD
    Short Term Debt4,043,000USD12,896,000USD7,777,000USD12,587,000USD5,057,000USD6,284,000USD7,252,000USD—
    Short Long Term Debt1,000,000USD———————
    Short Long Term Debt Total48,444,000USD58,261,000USD75,862,000USD85,446,000USD71,531,000USD51,659,000USD11,500,000USD—
    Short Term Investments133,902,000USD208,087,000USD164,979,000USD240,114,000USD426,181,000USD562,108,000USD293,112,000USD386,371,000USD
    Net Receivables82,448,000USD69,340,000USD151,000USD0USD————
    Inventory51,678,000USD51,520,000USD10,372,000USD0USD————
    Accounts Payable22,159,000USD27,509,000USD33,123,000USD26,603,000USD27,377,000USD13,513,000USD15,567,000USD2,739,000USD
    Property Plant Equipment Net177,011,000USD164,282,000USD176,545,000USD178,247,000USD169,921,000USD113,915,000USD19,231,000USD2,683,000USD
    Property Plant Equipment Gross225,781,000USD200,302,000USD204,458,000USD194,965,000USD178,610,000USD113,915,000USD19,231,000USD2,683,000USD
    Accumulated Other Comprehensive Income16,440,000USD-1,046,000USD2,526,000USD-902,000USD-601,000USD19,000USD220,000USD-42,000USD
    Common Stock Shares Outstanding357,345,000shares289,877,000shares235,131,000shares159,259,000shares153,406,000shares138,301,000shares124,336,000shares97,277,000shares
    Non Current Assets Total470,481,000USD453,408,000USD472,503,000USD184,866,000USD269,377,000USD132,358,000USD28,162,000USD5,447,000USD
    Non Current Liabilities Total76,229,000USD77,680,000USD85,432,000USD72,859,000USD66,474,000USD57,089,000USD6,600,000USD230,000USD
    Non Currrent Assets Other14,146,000USD6,728,000USD270,000USD6,619,000USD7,868,000USD18,443,000USD8,931,000USD2,764,000USD
    Net Working Capital304,331,000USD334,677,000USD197,542,000USD387,631,000USD418,756,000USD581,229,000USD277,409,000USD460,976,000USD
    Unclassified Non Current Liabilities76,229,000USD76,680,000USD84,432,000USD71,859,000USD—-11,714,000USD-2,352,000USD—
    Unclassified Equity3,457,637,000USD3,095,974,000USD2,594,437,000USD2,068,859,000USD1,794,688,000USD1,486,656,000USD869,349,000USD838,979,000USD
    Long Term Debt—1,000,000USD1,000,000USD1,000,000USD1,000,000USD———
    Current Deferred Revenue——1USD—————
    Unclassified Non Current Assets——66,430,000USD-185,707,000USD-777,333,000USD-73,199,000USD-8,931,000USD-2,764,000USD
    Other Assets———185,707,000USD777,333,000USD73,199,000USD8,931,000USD2,764,000USD
    Long Term Investments———0USD91,588,000USD0USD——
    Net Tangible Assets———499,635,000USD621,656,000USD656,494,000USD298,967,000USD466,187,000USD
    Non Current Liabilities Other————65,474,000USD57,089,000USD6,600,000USD—
    Other Liab—————11,714,000USD2,352,000USD230,000USD
    Deferred Long Term Liab———————230,000USD
    Unclassified Current Assets———————-6,851,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-79,045,000USD-71,904,000USD-91,253,000USD-111,658,000USD-116,163,000USD-78,559,000USD-83,541,000USD-97,101,000USD
    Depreciation7,592,000USD17,861,000USD11,677,000USD11,938,000USD11,065,000USD11,687,000USD11,148,000USD10,864,000USD
    Stock Based Compensation11,269,000USD11,817,000USD11,900,000USD14,943,000USD22,915,000USD30,977,000USD31,006,000USD30,466,000USD
    Other Non Cash Items1,659,000USD-3,230,000USD-88,000USD6,152,000USD-2,043,000USD-981,000USD-2,748,000USD-2,489,000USD
    Change To Account Receivables690,000USD-15,687,000USD-6,823,000USD11,000,000USD-1,598,000USD-13,572,000USD-24,164,000USD-31,370,000USD
    Change To Inventory-4,931,000USD-4,001,000USD-3,182,000USD6,942,000USD-13,970,000USD-13,450,000USD-10,873,000USD-8,859,000USD
    Change In Working Capital-12,884,000USD-7,293,000USD-8,533,000USD9,190,000USD-17,630,000USD-37,979,000USD-13,317,000USD-38,711,000USD
    Total Cash From Operating Activities-72,074,000USD-52,565,000USD-78,702,000USD-67,447,000USD-103,694,000USD-73,296,000USD-58,973,000USD-98,429,000USD
    Capital Expenditures-6,608,000USD-9,320,000USD-10,844,000USD-7,461,000USD-6,211,000USD-4,168,000USD-2,288,000USD-442,000USD
    Free Cash Flow-78,682,000USD-61,885,000USD-89,546,000USD-74,908,000USD-109,905,000USD-77,464,000USD-61,261,000USD-98,871,000USD
    Investments18,002,000USD10,095,000USD17,012,000USD13,842,000USD15,867,000USD23,677,000USD-48,801,000USD40,219,000USD
    Total Cashflows From Investing Activities11,394,000USD775,000USD17,012,000USD13,842,000USD15,867,000USD23,677,000USD-48,801,000USD40,219,000USD
    Total Cash From Financing Activities94,335,000USD56,172,000USD88,056,000USD13,230,000USD143,315,000USD2,309,000USD41,954,000USD152,825,000USD
    Issuance Of Capital Stock98,514,000USD55,778,000USD88,520,000USD13,065,000USD148,944,000USD0USD47,518,000USD151,873,000USD
    Change In Cash-157,086,000USD4,959,000USD25,686,000USD-39,636,000USD55,996,000USD-48,492,000USD-64,567,000USD94,490,000USD
    Begin Period Cash Flow163,078,000USD164,099,000USD138,413,000USD178,049,000USD122,053,000USD164,186,000USD235,108,000USD140,618,000USD
    End Period Cash Flow5,992,000USD169,058,000USD164,099,000USD138,413,000USD178,049,000USD115,694,000USD170,541,000USD235,108,000USD
    Other Cashflows From Financing Activities-4,179,000USD-445,000USD-466,000USD165,000USD-5,629,000USD-880,000USD-5,564,000USD952,000USD
    Sale Purchase Of Stock—170,000USD671,000USD———7,263,000USD-1,000,000USD
    Unclassified Financing Cash Flow—56,447,000USD87,851,000USD——3,189,000USD40,255,000USD152,873,000USD
    Unclassified Operating Cash Flow——-2,405,000USD1,988,000USD-1,838,000USD1,559,000USD-1,521,000USD-1,458,000USD
    Unclassified Investing Cash Flow——10,844,000USD7,461,000USD6,211,000USD4,168,000USD2,288,000USD-40,219,000USD
    Other Cashflows From Investing Activities———————40,661,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20202020-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Net Income-390,978,000USD-372,177,000USD-444,037,000USD-259,581,000USD-123,580,000USD-92,064,000USD-52,894,000USD-27,660,000USD
    Depreciation34,462,000USD43,606,000USD33,127,000USD1,140,000USD956,000USD952,000USD978,000USD999,000USD
    Stock Based Compensation61,575,000USD109,627,000USD62,625,000USD40,887,000USD20,027,000USD11,968,000USD18,904,000USD8,523,000USD
    Other Non Cash Items18,870,000USD-8,649,000USD-3,535,000USD7,572,000USD-1,323,000USD19,000USD-74,000USD8,523,000USD
    Change To Account Receivables-13,108,000USD-69,189,000USD-149,000USD——0USD0USD0USD
    Change To Inventory-14,211,000USD-39,917,000USD-10,118,000USD——0USD0USD0USD
    Change In Working Capital-24,266,000USD-122,556,000USD-6,521,000USD2,983,000USD2,671,000USD416,000USD418,000USD-243,000USD
    Total Cash From Operating Activities-302,408,000USD-352,977,000USD-361,820,000USD-205,134,000USD-101,249,000USD-78,709,000USD-32,668,000USD-18,381,000USD
    Capital Expenditures-33,836,000USD-11,069,000USD-22,290,000USD-46,791,000USD-1,198,000USD-1,028,000USD-1,521,000USD-1,143,000USD
    Free Cash Flow-336,244,000USD-364,046,000USD-384,110,000USD-251,925,000USD-102,447,000USD-79,737,000USD-34,189,000USD-19,524,000USD
    Investments81,332,000USD-96,411,000USD-81,936,000USD-271,062,000USD-385,081,000USD59,705,000USD10,415,000USD-70,065,000USD
    Total Cashflows From Investing Activities47,496,000USD-96,411,000USD-155,242,000USD-317,853,000USD-386,279,000USD58,677,000USD8,894,000USD-91,153,000USD
    Total Cash From Financing Activities300,773,000USD390,664,000USD462,959,000USD576,422,000USD424,307,000USD58,688,000USD96,904,000USD78,267,000USD
    Sale Purchase Of Stock1,510,000USD—2,410,000USD-284,000USD-223,000USD-1,252,000USD-642,000USD78,267,000USD
    Issuance Of Capital Stock306,307,000USD397,304,000USD652,782,000USD567,043,000USD398,817,000USD———
    Change In Cash47,384,000USD-59,265,000USD-56,843,000USD53,435,000USD-63,221,000USD38,656,000USD73,130,000USD-31,267,000USD
    Begin Period Cash Flow122,053,000USD181,318,000USD238,161,000USD19,419,000USD145,373,000USD106,717,000USD33,587,000USD44,909,000USD
    End Period Cash Flow169,058,000USD122,053,000USD181,318,000USD72,854,000USD82,152,000USD145,373,000USD106,717,000USD13,642,000USD
    Other Cashflows From Financing Activities-7,059,000USD-6,640,000USD-322,000USD9,379,000USD25,490,000USD58,688,000USD146,358,000USD9,960,000USD
    Unclassified Financing Cash Flow306,322,000USD—460,871,000USD566,327,000USD398,040,000USD1,252,000USD—-9,960,000USD
    Unclassified Investing Cash Flow—11,069,000USD-51,016,000USD271,062,000USD385,081,000USD-59,705,000USD-10,415,000USD—
    Net Borrowings——0USD1,000,000USD1,000,000USD———
    Change To Liabilities———21,145,000USD4,736,000USD4,924,000USD3,183,000USD-32,000USD
    Cash And Cash Equivalents Changes———53,435,000USD-63,221,000USD38,656,000USD73,130,000USD-31,267,000USD
    Other Cashflows From Investing Activities———-271,062,000USD-385,081,000USD59,705,000USD10,415,000USD-19,945,000USD
    Dividends Paid—————0USD-49,454,000USD0USD
    Unclassified Operating Cash Flow———————-8,523,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational346,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States98,967,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductAmtagvi90,721,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProleukin8,592,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational958,000USD0001104659-26-056778
    Q1 2026Quarterly · 2026-03-31GeographyUnited States70,472,000USD0001104659-26-056778
    Q1 2026Quarterly · 2026-03-31ProductAmtagvi60,222,000USD0001104659-26-056778
    Q1 2026Quarterly · 2026-03-31ProductProleukin11,208,000USD0001104659-26-056778
    Q4 2025Quarterly · 2025-12-31GeographyInternational1,285,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States85,486,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductAmtagvi64,897,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductProleukin21,874,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational4,489,000USD0001104659-26-018899
    FY 2025Yearly · 2025-12-31GeographyUnited States259,013,000USD0001104659-26-018899
    FY 2025Yearly · 2025-12-31ProductAmtagvi220,024,000USD0001104659-26-018899
    FY 2025Yearly · 2025-12-31ProductProleukin43,478,000USD0001104659-26-018899
    Q3 2025Quarterly · 2025-09-30GeographyInternational1,053,000USD0001104659-25-107470
    Q3 2025Quarterly · 2025-09-30GeographyUnited States66,402,000USD0001104659-25-107470
    Q3 2025Quarterly · 2025-09-30ProductAmtagvi57,482,000USD0001104659-25-107470
    Q3 2025Quarterly · 2025-09-30ProductProleukin9,973,000USD0001104659-25-107470
    Q2 2025Quarterly · 2025-06-30GeographyInternational1,347,000USD0001558370-25-010807
    Q2 2025Quarterly · 2025-06-30GeographyUnited States58,605,000USD0001558370-25-010807
    Q2 2025Quarterly · 2025-06-30ProductAmtagvi54,074,000USD0001558370-25-010807
    Q2 2025Quarterly · 2025-06-30ProductProleukin5,878,000USD0001558370-25-010807
    Q1 2025Quarterly · 2025-03-31GeographyInternational804,000USD0001104659-26-056778
    Q1 2025Quarterly · 2025-03-31GeographyUnited States48,520,000USD0001104659-26-056778
    Q1 2025Quarterly · 2025-03-31ProductAmtagvi43,571,000USD0001104659-26-056778
    Q1 2025Quarterly · 2025-03-31ProductProleukin5,753,000USD0001104659-26-056778
    Q4 2024Quarterly · 2024-12-31GeographyInternational515,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States73,194,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational3,027,000USD0001104659-26-018899
    FY 2024Yearly · 2024-12-31GeographyUnited States161,043,000USD0001104659-26-018899
    FY 2024Yearly · 2024-12-31ProductAmtagvi103,567,000USD0001104659-26-018899
    FY 2024Yearly · 2024-12-31ProductProleukin60,503,000USD0001104659-26-018899
    Q3 2024Quarterly · 2024-09-30GeographyInternational740,000USD0001104659-25-107470
    Q3 2024Quarterly · 2024-09-30GeographyUnited States57,815,000USD0001104659-25-107470
    Q3 2024Quarterly · 2024-09-30ProductAmtagvi42,038,000USD0001104659-25-107470
    Q3 2024Quarterly · 2024-09-30ProductProleukin16,517,000USD0001104659-25-107470
    Q2 2024Quarterly · 2024-06-30ProductAmtagvi12,819,000USD0001558370-25-010807
    Q2 2024Quarterly · 2024-06-30ProductProleukin18,287,000USD0001558370-25-010807
    FY 2023Yearly · 2023-12-31GeographyInternational1,200,000USD0001558370-24-002036
    FY 2023Yearly · 2023-12-31GeographyUnited States0USD0001558370-24-002036

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.